APONTIS PHARMA AG Germany - Health Care / Pharma

Buy (old: Buy)

Price target: EUR 25.00 (old: EUR 25.00)

Price:	EUR 7.96	Next result:	tbd
Bloomberg:	APPH GR	Market cap:	EUR 67.7 m
Reuters:	APPHG.DE	Enterprise Value:	EUR 44.4 m

The short-term setbacks obscure the unfolding growth story

Amid the recent streak of setbacks with two "legacy" Single Pills (Caramlo and Atorimib), the **market is seemingly questioning the company's ability to scale the attractive economics of the Single Pill business** (>65% gross margin) and reach the targeted 30% EBITDA margin. Following the most recent setback with Atorimib – partially due to manufacturing disruptions at a CMO – the share price has fallen to its all-time-lows.

In short, **APONTIS had to lower Single Pill sales expectations by** \in **9m** for '23E from \in 43m to \in 52m largely due to Atorimib supply bottlenecks, on top of tender headwinds and the delayed launch of a Single Pill. Due to missing high-margin Single Pill sales and as a result poor fixed costs coverage, **EBIT forecast was lowered by** \in **6.4m, reflecting a decremental margin of 70%**. This represents the "worst case" of no additional Atorimib supply beyond guaranteed volumes.

While these setbacks impact the short-term financials – with an especially pronounced effect due to still small scale – **this has no bearing on structural economics and growth prospects of the Single Pills business**. In fact, the key elements of the Single Pills growth story not only remain intact, but continue to take shape.

- **Single Pills gain traction:** Increasing clinical evidence in favor of Single Pills coupled with management's efforts to foster patient conversion with structured digital processes (e.g. Single-Pill-Finder) should accelerate the adoption of Single Pills.
- Dynamic growth of the Single Pill portfolio: By '24E, APONTIS is on track to grow its Single Pill portfolio by 8 additional products to the total of 18. Another 11 Single Pills (thereof 4 "in advanced negotiations") are scheduled to be launched by '26E to the total of 29. The long-term pipeline comprises further 15 projects under evaluation.
- Strong scalability supports earnings growth: By '26/27E, APONTIS looks set to add € 20m of gross profit from the 8 pills to be launched in 2023-24E and another € 6m from the existing 10 Single Pills conservatively assuming 10% sales CAGR. With a scalable cost base (70%+ fixed costs ratio), an EBITDA of c. € 18m should be well in reach. This would correspond to mere 2x EV/EBITDA. Even when assuming a slower uptake of the new launches, EBITDA would still amount to € 12m+, corresponding to 3x EV/EBITDA (*next page*).

Reiterate **BUY** with an unchanged **PT of € 25** based on DCF.

Y/E 31.12 (EUR m)	2020	2021	2022	2023E	2024E	2025E	2026E
Sales	39.2	51.2	55.7	42.6	56.9	68.1	78.8
Sales growth	-2 %	30 %	9%	-24 %	34 %	20 %	16 %
EBITDA	1.0	5.9	5.6	-2.3	6.0	12.2	18.1
EBIT	-0.6	4.1	3.8	-4.7	2.1	7.9	12.5
Net income	-1.2	2.7	2.7	-3.6	1.6	6.0	9.5
Net debt	6.0	-29.8	-36.3	-25.9	-27.3	-34.0	-45.5
Net gearing	140.9 %	-72.1 %	-87.0 %	-67.9 %	-68.6 %	-74.3 %	-82.3 %
Net Debt/EBITDA	5.7	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	-0.14	0.32	0.32	-0.42	0.19	0.71	1.12
CPS	-0.02	0.20	1.09	-0.67	0.10	0.64	1.05
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend yield	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Gross profit margin	63.8 %	66.0 %	62.8 %	68.1 %	71.0 %	71.7 %	73.3 %
EBITDA margin	2.7 %	11.5 %	10.1 %	-5.5 %	10.5 %	18.0 %	22.9 %
EBIT margin	-1.6 %	8.1 %	6.8 %	-11.0 %	3.6 %	11.6 %	15.8 %
ROCE	-1.9 %	7.4 %	17.3 %	-12.1 %	5.1 %	19.8 %	20.8 %
EV/sales	1.9	0.8	0.6	1.0	0.8	0.5	0.3
EV/EBITDA	73.0	6.8	6.1	-19.1	7.2	3.0	1.4
EV/EBIT	-123.6	9.7	8.9	-9.5	20.8	4.6	2.0
PER	-57.2	24.7	24.8	-19.0	42.8	11.2	7.1
Adjusted FCF yield	-0.4 %	8.0 %	8.2 %	-8.2 %	3.7 %	16.9 %	39.3 %

Source: Company data, Hauck Aufhäuser Investment Banking Close price as of: 23.05.2023

Please refer to important disclosures at the end of the report



23-May-23

Alexander Galitsa Analyst

alexander.galitsa@ha-ib.de

Tel.: +49 40 414 3885 83



Source: Company data, Hauck Aufhäuser Investment Banking

High/low 52 weeks:	13.85 / 6.02							
Price/Book Ratio:	1.9							
Relative performance (SDAX):								
3 months	3.1 %							
6 months	-4.4 %							
12 months	-38.5 %							

Changes in estimates

		Sales	EBIT	EPS
2023	old:	42.6	-4.7	-0.42
2025	Δ	-	-	-
2024	old:	56.9	2.1	0.19
2024	Δ	-	-	-
2025	old:	68.1	7.9	0.71
2023	Δ	-	-	-

Key share data:

Number of shares: (in m pcs)	8.5
Authorised capital: (in € m)	-
Book value per share: (in €)	4.5
Ø trading volume: (12 months)	-


Major shareholders:

Free float	55.5 %
Paragon Partners	36.3 %
Management	8.2 %


Company description:

Pharma company with a rich heritage and own-IP products in the field of Single Pills for cardiovascular diseases

EBITDA bridge 2023-26E



Source: Company data; Hauck Aufhäuser Investment Banking



EBITDA bridge 2023-26E (30% discount to the uptake of new Single Pills)

Source: Company data; HAIB

Financials

Profit and loss (EUR m)	2020	2021	2022	2023E	2024E	2025E	2026E
Net sales	39.2	51.2	55.7	42.6	56.9	68.1	78.8
Sales growth	-2.0 %	30.4 %	8.9 %	-23.6 %	33.6 %	19.7 %	15.7 %
Increase/decrease in finished goods and work-in-process	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total sales	39.2	51.2	55.7	42.6	56.9	68.1	78.8
Other operating income	2.6	7.1	2.6	1.1	1.3	1.4	1.4
Material expenses	14.2	17.4	20.7	13.6	16.5	19.3	21.0
Personnel expenses	16.5	19.7	17.7	19.6	21.0	22.3	23.8
Other operating expenses	10.1	15.3	14.4	12.9	14.8	15.6	17.3
Total operating expenses	38.2	45.3	50.1	44.9	50.9	55.9	60.7
EBITDA	1.0	5.9	5.6	-2.3	6.0	12.2	18.1
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITA	1.0	5.9	5.6	-2.3	6.0	12.2	18.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.6	1.7	1.8	2.4	3.9	4.3	5.6
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	-0.6	4.1	3.8	-4.7	2.1	7.9	12.5
Interest income	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Interest expenses	0.9	0.4	0.0	0.0	0.0	0.0	0.0
Other financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	-0.9	-0.4	0.0	0.0	0.0	0.0	0.0
Recurring pretax income from continuing operations	-1.5	3.7	3.8	-4.7	2.1	7.9	12.5
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	-1.5	3.7	3.8	-4.7	2.1	7.9	12.5
Taxes	-0.3	1.0	1.1	-1.1	0.5	1.9	3.0
Net income from continuing operations	-1.2	2.7	2.7	-3.6	1.6	6.0	9.5
Result from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-1.2	2.7	2.7	-3.6	1.6	6.0	9.5
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit (reported)	-1.2	2.7	2.7	-3.6	1.6	6.0	9.5
Average number of shares	8.5	8.5	8.5	8.5	8.5	8.5	8.5
EPS reported	-0.14	0.32	0.32	-0.42	0.19	0.71	1.12

Profit and loss (common size)	2020	2021	2022	2023E	2024E	2025E	2026E
Net sales	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
Increase/decrease in finished goods and work-in-process	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Total sales	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %
Other operating income	6.7 %	13.9 %	4.7 %	2.6 %	2.3 %	2.0 %	1.7 %
Material expenses	36.2 %	34.0 %	37.2 %	31.9 %	29.0 %	28.3 %	26.7 %
Personnel expenses	42.1 %	38.4 %	31.7 %	45.9 %	36.9 %	32.8 %	30.2 %
Other operating expenses	25.8 %	30.0 %	25.8 %	30.3 %	26.0 %	22.9 %	21.9 %
Total operating expenses	97.3 %	88.5 %	89.9 %	105.5 %	89.5 %	82.0 %	77.1 %
EBITDA	2.7 %	11.5 %	10.1 %	neg.	10.5 %	18.0 %	22.9 %
Depreciation	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
EBITA	2.6 %	11.4 %	10.0 %	neg.	10.5 %	17.9 %	22.9 %
Amortisation of goodwill	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Amortisation of intangible assets	4.1 %	3.4 %	3.2 %	5.5 %	6.8 %	6.3 %	7.1 %
Impairment charges	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
EBIT (inc revaluation net)	neg.	8.1 %	6.8 %	neg.	3.6 %	11.6 %	15.8 %
Interest income	0.0 %	0.0 %	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %
Interest expenses	2.2 %	0.8 %	0.1 %	0.0 %	0.0 %	0.0 %	0.0 %
Other financial result	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Financial result	neg.	neg.	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Recurring pretax income from continuing operations	neg.	7.3 %	6.9 %	neg.	3.7 %	11.6 %	15.8 %
Extraordinary income/loss	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Earnings before taxes	neg.	7.3 %	6.9 %	neg.	3.7 %	11.6 %	15.8 %
Tax rate	22.8 %	20.0 %	24.0 %	24.0 %	24.0 %	24.0 %	24.0 %
Net income from continuing operations	neg.	5.3 %	4.9 %	neg.	2.8 %	8.8 %	12.0 %
Income from discontinued operations (net of tax)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Net income	neg.	5.3 %	4.9 %	neg.	2.8 %	8.8 %	12.0 %
Minority interest	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Net profit (reported)	neg.	5.3 %	4.9 %	neg.	2.8 %	8.8 %	12.0 %

Balance sheet (EUR m)	2020	2021	2022	2023E	2024E	2025E	2026E
Intangible assets	14.8	14.7	16.1	20.9	20.3	19.0	16.5
Property, plant and equipment	0.0	0.0	0.0	0.1	0.1	0.1	0.1
Financial assets	0.7	0.8	0.8	0.8	0.8	0.8	0.8
FIXED ASSETS	15.5	15.5	17.0	21.7	21.2	19.9	17.3
Inventories	2.9	4.6	3.2	3.0	4.1	4.9	5.6
Accounts receivable	1.2	2.9	2.4	1.8	2.4	2.9	3.3
Other current assets	1.3	1.1	1.0	1.0	1.0	1.0	1.0
Liquid assets	8.1	29.8	36.3	25.9	27.3	34.0	45.5
Deferred taxes	0.7	0.2	0.0	0.0	0.0	0.0	0.0
Deferred charges and prepaid expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	14.2	38.6	42.9	31.8	34.8	42.7	55.4
TOTAL ASSETS	29.7	54.1	59.9	53.5	55.9	62.6	72.8
SHAREHOLDERS EQUITY	4.2	41.4	41.8	38.2	39.8	45.8	55.3
MINORITY INTEREST	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-term debt	14.0	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	2.3	2.4	2.7	2.7	2.7	2.7	2.7
Other provisions	4.8	6.6	8.8	8.8	8.8	8.8	8.8
Non-current liabilities	21.1	9.0	11.5	11.5	11.5	11.5	11.5
short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	3.3	3.0	5.4	2.6	3.4	4.1	4.7
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	1.1	0.7	1.3	1.3	1.3	1.3	1.3
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	4.4	3.7	6.6	3.8	4.7	5.4	6.0
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	29.7	54.1	59.9	53.5	55.9	62.6	72.8

Balance sheet (common size)	2020	2021	2022	2023E	2024E	2025E	2026E
Intangible assets	49.7 %	27.1 %	27.0 %	39.0 %	36.3 %	30.4 %	22.6 %
Property, plant and equipment	0.1 %	0.0 %	0.1 %	0.1 %	0.1 %	0.1 %	0.1 %
Financial assets	2.2 %	1.4 %	1.3 %	1.5 %	1.4 %	1.3 %	1.1 %
FIXED ASSETS	52.1 %	28.6 %	28.4 %	40.6 %	37.9 %	31.8 %	23.8 %
Inventories	9.8 %	8.5 %	5.3 %	5.7 %	7.3 %	7.8 %	7.7 %
Accounts receivable	4.1 %	5.4 %	3.9 %	3.4 %	4.3 %	4.6 %	4.6 %
Other current assets	4.3 %	2.0 %	1.7 %	1.9 %	1.8 %	1.6 %	1.4 %
Liquid assets	27.1 %	55.1 %	60.7 %	48.5 %	48.8 %	54.3 %	62.5 %
Deferred taxes	2.5 %	0.3 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Deferred charges and prepaid expenses	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
CURRENT ASSETS	47.9 %	71.4 %	71.6 %	59.4 %	62.1 %	68.2 %	76.2 %
TOTAL ASSETS	100.0 %	100.0 %	99.9 %	100.0 %	100.0 %	100.0 %	100.0 %
SHAREHOLDERS EQUITY	14.2 %	76.5 %	69.8 %	71.4 %	71.1 %	73.1 %	75.9 %
MINORITY INTEREST	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Long-term debt	47.2 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Provisions for pensions and similar obligations	7.6 %	4.5 %	4.5 %	5.0 %	4.8 %	4.3 %	3.7 %
Other provisions	16.3 %	12.1 %	14.7 %	16.5 %	15.7 %	14.1 %	12.1 %
Non-current liabilities	71.1 %	16.6 %	19.2 %	21.5 %	20.5 %	18.3 %	15.8 %
short-term liabilities to banks	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Accounts payable	11.0 %	5.5 %	8.9 %	4.8 %	6.1 %	6.6 %	6.5 %
Advance payments received on orders	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Other liabilities (incl. from lease and rental contracts)	3.7 %	1.3 %	2.1 %	2.4 %	2.3 %	2.0 %	1.7 %
Deferred taxes	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Deferred income	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Current liabilities	14.7 %	6.9 %	11.1 %	7.2 %	8.4 %	8.6 %	8.3 %
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %

Cash flow statement (EUR m)	2020	2021	2022	2023E	2024E	2025E	2026E
Net profit/loss	-1.2	-0.7	2.7	-3.6	1.6	6.0	9.5
Depreciation of fixed assets (incl. leases)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.6	1.7	1.8	2.4	3.9	4.3	5.6
Others	-0.3	6.1	2.1	0.0	0.0	0.0	0.0
Cash flow from operations before changes in w/c	0.2	7.1	6.7	-1.2	5.5	10.3	15.1
Increase/decrease in inventory	1.3	-1.7	1.4	0.1	-1.0	-0.8	-0.8
Increase/decrease in accounts receivable	-0.1	-1.7	0.6	0.6	-0.6	-0.5	-0.5
Increase/decrease in accounts payable	0.1	-0.3	2.4	-2.8	0.9	0.7	0.6
Increase/decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in working capital	1.3	-3.6	4.4	-2.1	-0.8	-0.6	-0.6
Cash flow from operating activities	1.5	3.4	11.0	-3.3	4.7	9.7	14.5
CAPEX	0.7	1.7	3.3	7.1	3.4	3.0	3.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.1	0.1	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.7	0.0	0.0	0.0	0.0
Cash flow from investing activities	-0.8	-1.8	-2.7	-7.1	-3.4	-3.0	-3.0
Cash flow before financing	0.7	1.7	8.3	-10.4	1.4	6.7	11.5
Increase/decrease in debt position	0.0	-12.3	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	38.0	-1.8	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	-5.6	0.0	0.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	0.0	20.1	-1.8	0.0	0.0	0.0	0.0
Increase/decrease in liquid assets	0.7	21.8	6.5	-10.4	1.4	6.7	11.5
Liquid assets at end of period	8.1	29.8	36.3	25.9	27.3	34.0	45.5

Source: Company data, Hauck Aufhäuser Investment Banking

Regional split (EUR m)	2020	2021	2022	2023E	2024E	2025E	2026E
Domestic	39.2	51.2	55.7	42.6	56.9	68.1	78.8
yoy change	-2.0 %	30.4 %	8.9 %	-23.6 %	33.6 %	19.7 %	15.7 %
Rest of Europe	n/a	n/a	n/a	n/a	n/a	n/a	n/a
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NAFTA	n/a	n/a	n/a	n/a	n/a	n/a	n/a
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Asia Pacific	n/a	n/a	n/a	n/a	n/a	n/a	n/a
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Rest of world	n/a	n/a	n/a	n/a	n/a	n/a	n/a
yoy change	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TTL	39.2	51.2	55.7	42.6	56.9	68.1	78.8
yoy change	-2.0 %	30.4 %	8.9 %	-23.6 %	33.6 %	19.7 %	15.7 %

		0004	0000	00005	00045	00055	00005
Key ratios (EUR m)	2020	2021	2022	2023E	2024E	2025E	2026E
P&L growth analysis							
Sales growth	-2.0 %	30.4 %	8.9 %	-23.6 %	33.6 %	19.7 %	15.7 %
EBITDA growth	-162.1 %	465.3 %	-4.6 %	-141.4 %	-357.4 %	104.4 %	47.8 %
EBIT growth	-72.3 %	-773.0 %	-7.8 %	-223.2 %	-144.0 %	282.3 %	57.8 %
EPS growth	-50.0 %	-331.5 %	-0.4 %	-230.5 %	-144.4 %	280.6 %	57.8 %
Efficiency							
Total operating costs / sales	97.3 %	88.5 %	89.9 %	105.5 %	89.5 %	82.0 %	77.1 %
Sales per employee	196.7	253.4	267.3	197.7	254.0	291.6	323.0
EBITDA per employee	5.2	29.1	26.9	-10.8	26.7	52.4	74.1
Balance sheet analysis							
Avg. working capital / sales	6.0 %	6.5 %	0.9 %	8.0 %	2.8 %	4.3 %	2.8 %
Inventory turnover (sales/inventory)	13.4	11.1	17.6	14.0	14.0	14.0	14.0
Trade debtors in days of sales	11.4	20.8	15.4	15.4	15.4	15.4	15.4
A/P turnover [(A/P*365)/sales]	30.3	21.4	35.1	22.0	22.0	22.0	22.0
Cash conversion cycle (days)	2.8	54.3	-23.2	28.2	29.5	29.8	30.6
Cash flow analysis							
Free cash flow	0.7	1.8	7.7	-10.4	1.4	6.7	11.5
Free cash flow/sales	1.8 %	3.5 %	13.9 %	-24.4 %	2.4 %	9.8 %	14.6 %
FCF / net profit	neg.	64.8 %	283.9 %	neg.	85.9 %	111.4 %	120.9 %
Capex / depn	47.0 %	102.0 %	185.5 %	299.6 %	86.2 %	70.3 %	54.4 %
Capex / maintenance capex	0.1 %	0.6 %	4.7 %	1.3 %	0.8 %	0.7 %	0.5 %
Capex / maintenance capex Capex / sales	0.1 % n/a	0.0 % n/a	4.7 % n/a	n/a	0.0 % n/a	0.7 /8 n/a	0.3 % n/a
Security	11/d	n/a	11/a	Ti/d	n/a	n/a	11/a
Net debt	6.0	20.9	26.2	-25.9	27.2	-34.0	1E E
Net Debt/EBITDA		-29.8	-36.3		-27.3		-45.5
	5.7	0.0	0.0	0.0	0.0	0.0	0.0
Net debt / equity	1.4	neg.	neg.	neg.	neg.	neg.	neg.
Interest cover	0.0	10.2	79.5	999.0	999.0	999.0	999.0
Dividend payout ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Asset utilisation	4.5	4.0	1.0	0.0		10	10
Capital employed turnover	1.5	1.0	1.0	0.9	1.1	1.2	1.2
Operating assets turnover	42.1	11.3	276.4	18.3	18.3	18.3	18.4
Plant turnover	954.2	2,740.5	1,250.7	715.3	818.0	856.0	990.5
Inventory turnover (sales/inventory)	13.4	11.1	17.6	14.0	14.0	14.0	14.0
Returns							
ROCE	-1.9 %	7.4 %	17.3 %	-12.1 %	5.1 %	19.8 %	20.8 %
ROE	-28.0 %	6.6 %	6.5 %	-9.3 %	4.0 %	13.1 %	17.2 %
Other							
Interest paid / avg. debt	6.6 %	6.1 %	0.7 %	n/a	n/a	n/a	n/a
No. employees (average)	200	202	209	216	224	234	244
Number of shares	8.5	8.5	8.5	8.5	8.5	8.5	8.5
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	-0.14	0.32	0.32	-0.42	0.19	0.71	1.12
Valuation ratios							
P/BV	16.0	1.6	1.6	1.8	1.7	1.5	1.2
EV/sales	1.9	0.8	0.6	1.0	0.8	0.5	0.3
EV/EBITDA	73.0	6.8	6.1	-19.1	7.2	3.0	1.4
EV/EBITA	74.9	6.9	6.1	-19.0	7.2	3.0	1.4
EV/EBIT	-123.6	9.7	8.9	-9.5	20.8	4.6	2.0
EV/FCF	105.2	22.7	4.4	-4.3	31.7	5.4	2.2
Adjusted FCF yield	-0.4 %	8.0 %	8.2 %	-8.2 %	3.7 %	16.9 %	39.3 %
Dividend yield	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Source: Company data, Housk Aufhäuser Investment Penking							

Disclosures regarding research publications of Hauck Aufhäuser Lampe Privatbank AG pursuant to section 85 of the German Securities Trading Act (WpHG) and distributed in the UK under the Temporary Permission Regime for EEA firms, subject to the FCA requirements on research recommendation disclosures

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. Further to this, under the FCA's rules on research recommendations, any conflicts of interest in connection with the recommendation must be disclosed. A conflict of interest is presumed to exist in particular if Hauck Aufhäuser Lampe Privatbank AG

- (1) or any other person belonging to the same group with that person (as part of a consortium) within the past twelve months, acquired the financial instruments of the analysed company,
- (2) or any other person belonging to the same group with that person has entered into an agreement on the production of the research report with the analysed company,
- (3) has, within the past twelve months, been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement,
- (4) holds a) 5% or more of the share capital of the analysed company, or b) the analysed company holds 5% or more of the share capital of Hauck Aufhäuser Lampe Privatbank AG or its affiliate(s),
- (5) holds a net short (a) or a net long (b) position of 0.5% of the outstanding share capital of the analysed company or derivatives thereof,
- (6) or any other person belonging to the same group with that person is a market maker or liquidity provider in the financial instruments of the issuer,
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company or a significant conflict of interest with respect to the issuer,
- (8) The research report has been made available to the company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosure
APONTIS PHARMA AG	3, 6

Historical target price and rating changes for APONTIS PHARMA AG in the last 12 months



12.08.2022	Galitsa, Alexander	Buy	EUR 30.00	EUR 10.90
30.05.2022	Galitsa, Alexander	Buy	EUR 30.00	EUR 13.60

Hauck Aufhäuser Investment Banking distribution of ratings and in proportion to investment banking services

Buy	76.30 %	91.18 %
Sell	4.62 %	0.00 %
Hold	19.08 %	8.82 %

Date of publication creation: 23/05/2023 08:16 AM

Date of publication dissemination: 23/05/2023 08:16 AM

1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by Hauck Aufhäuser Lampe Privatbank AG, exclusively to selected recipients [in DE, GB, FR, CH, US, UK, Scandinavia, and Benelux or, in individual cases, also in other countries]. A distribution to private investors in the sense of the German Securities Trading Act (WpHG) is excluded. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of Hauck Aufhäuser Lampe Privatbank AG. Reproduction of this document, in whole or in part, is not permitted without prior permission Hauck Aufhäuser Lampe Privatbank AG. All rights reserved.

Under no circumstances shall Hauck Aufhäuser Lampe Privatbank AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

Hauck Aufhäuser Lampe Privatbank AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of Hauck Aufhäuser Lampe Privatbank AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjustment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

Hauck Aufhäuser Lampe Privatbank AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 10% within 12 months

Sell: Sustainable downside potential of more than 10% within 12 months. Hold: Upside/downside potential is limited. No immediate catalyst visible.

NB: The ratings of Hauck Aufhäuser Lampe Privatbank AG are not based on a performance that is expected to be "relative" to the market.

The decision on the choice of the financial instruments analysed in this document was solely made by Hauck Aufhäuser Lampe Privatbank AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of Hauck Aufhäuser Lampe Privatbank AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. Hauck Aufhäuser Lampe Privatbank AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

Hauck Aufhäuser Lampe Privatbank AG are under supervision of the BaFin – German Federal Financial Supervisory Authority Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

This document is distributed in the UK under the Temporary Permission Regime for EEA firms and in compliance with the applicable FCA requirements.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany. The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: https://www.hal-privatbank.com/en/investmentbank/investment-banking

Disclosures for U.S. persons only

This research report is a product of HAUCK AUFHÄUSER LAMPE PRIVATBANK AG, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by HAUCK AUFHÄUSER LAMPE PRIVATBANK AG, only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, HAUCK AUFHÄUSER LAMPE PRIVATBANK AG, has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Contacts: Hauck Aufhäuser Investment Banking

HAIB Research

Hauck Aufhäuser Investment Banking Mittelweg 16/17 20148 Hamburg Germany

Tim Wunderlich, CFA Head of Transactional Research Tel.: +49 40 414 3885 81 E-Mail: tim.wunderlich@ha-ib.de

Christian Glowa Analyst Tel.: +49 40 414 3885 95 E-Mail: christian.glowa@ha-ib.de

Jorge González Sadornil Analyst Tel.: +49 40 414 3885 84 E-Mail: jorge.gonzalez@ha-ib.de

Simon Keller, CFA Analyst Tel.: +49 40 414 388 573 E-Mail: simon.keller@ha-ib.de

HAIB Sales

Alexander Lachmann Equity Sales Tel.: +41 43 497 30 23 E-Mail: alexander.lachmann@ha-ib.de

Hugues Madelin Equity Sales Tel.: +33 1 78 41 40 62 E-Mail: hugues.madelin@ha-ib.de

Markus Scharhag Equity Sales Tel.: +49 89 23 93 2813 E-Mail: markus.scharhag@ha-ib.de

HAIB Trading

Hauck Aufhäuser Investment Banking Privatbank AG Mittelweg 16/17 20148 Hamburg Germany

Fin Schaffer Trading Tel.: +49 40 414 38 85 98 E-Mail: fin.schaffer@hal-privatbank.com

Tom Warlich Middle-Office Tel.: +49 40 414 3885 78 E-Mail: tom.warlich@hal-privatbank.com Hauck Aufhäuser Investment Banking Goetheplaza 9-11 60311 Frankfurt am Main Germany

Marie-Thérèse Grübner Head of Research Tel.: +49 40 450 6342 3097 E-Mail: marie-therese.gruebner@ha-ib.de

Christian Salis Analyst Tel.: +49 40 414 3885 96 E-Mail: christian.salis@ha-ib.de

Nicole Winkler Analyst Tel.: +49 69 2161 1856 E-Mail: nicole.winkler@ha-ib.de Tel.: +49 (0) 40 414 3885 91 Fax: +49 (0) 40 414 3885 71 E-Mail: research@ha-ib.de www.ha-research.de

Alexander Galitsa Analyst Tel.: +49 40 414 3885 83 E-Mail: alexander.galitsa@ha-ib.de

Jonah Emerson Analyst Tel.: +49 69 2161 1825 E-Mail: jonah.emerson @ha-ib.de

Simon Jouck Analyst Tel.: +49 40 450 6342 3093 E-Mail: simon.jouck@ha-ib.de

Carlos Becke Equity Sales Tel.: +44 203 84 107 97 E-Mail: carlos.becke@ha-ib.de

Imogen Voorspuy Equity Sales Tel: +44 203 84 107 98 E-Mail: imogen.voorspuy@ha-ib.de

Vincent Bischoff Equity Sales Tel.: +49 40 414 38 85 88 E-Mail: vincent.bischoff@ha-ib.de

Tel.: +49 40 414 3885 78 Fax: +49 40 414 3885 71 E-Mail: info@hal-privatbank.com www.hal-privatbank.com

Nils Carstens Trading Tel.: +49 40 414 38 85 85 E-Mail: nils.carstens@ha-ib.de

Martin Aruschanjan Middle-Office Tel.: + +49 40 450 6342 35 87 E-Mail: martin.aruschanjan@hal-privatbank.com Christian Bybjerg Equity Sales Tel.: +49 414 3885 74 E-Mail: christian.bybjerg@ha-ib.de

James Bonsor Equity Sales Tel.: +44 203 84 107 96 E-Mail: james.bonsor@ha-ib.de